Polaris Group (6550): Announcement Regarding Director Change in Subsidiary Liyang Biotech
Polaris Group (6550) announced a change in the board of directors for its subsidiary, Liyang Biotech. Due to a reappointment by the parent company, Director Chen Hong-wen resigned and was replaced by Hou Yu-hsiang.
📋 Article Processing Timeline
- 📰 Published: May 26, 2026 at 06:31
- 🔍 Collected: May 26, 2026 at 06:31 (0 min after Published)
- 🤖 AI Analyzed: May 26, 2026 at 06:48 (16 min after Collected)
Announcement Date: 2026-05-26
Time: 19:35:50
Company Code: 6550
Company Name: Polaris Group (6550)
Subject: Announcement regarding the change of director at subsidiary Liyang Biotech Pharmaceuticals Co., Ltd.
1. Date of change: 2026-05-25
2. Category of personnel: Natural Person Director
3. Former position and name: Chen Hong-wen, Director at Liyang Biotech
4. Profile of former director: Director at Liyang Biotech
5. New position and name: Hou Yu-hsiang, Director at Liyang Biotech
6. Profile of new director: HR Director at Liyang Biotech
7. Type of change: Resignation
8. Reason for change: Reappointment by parent company
9. Shares held by new director at time of appointment: N/A
10. Former term: N/A
11. Effective date: N/A
12. Ratio of director changes in the same term: N/A
13. Ratio of independent director changes in the same term: N/A
14. Ratio of supervisor changes in the same term: N/A
15. Changes involve more than 1/3 of the board: No
16. Other information: This event does not have a material impact on shareholders' equity or security prices.
This personnel change is part of routine corporate management and organizational adjustments within the group.
Time: 19:35:50
Company Code: 6550
Company Name: Polaris Group (6550)
Subject: Announcement regarding the change of director at subsidiary Liyang Biotech Pharmaceuticals Co., Ltd.
1. Date of change: 2026-05-25
2. Category of personnel: Natural Person Director
3. Former position and name: Chen Hong-wen, Director at Liyang Biotech
4. Profile of former director: Director at Liyang Biotech
5. New position and name: Hou Yu-hsiang, Director at Liyang Biotech
6. Profile of new director: HR Director at Liyang Biotech
7. Type of change: Resignation
8. Reason for change: Reappointment by parent company
9. Shares held by new director at time of appointment: N/A
10. Former term: N/A
11. Effective date: N/A
12. Ratio of director changes in the same term: N/A
13. Ratio of independent director changes in the same term: N/A
14. Ratio of supervisor changes in the same term: N/A
15. Changes involve more than 1/3 of the board: No
16. Other information: This event does not have a material impact on shareholders' equity or security prices.
This personnel change is part of routine corporate management and organizational adjustments within the group.
FAQ
Does this director change affect the stock price?
According to the announcement, this change is not expected to have a material impact on shareholders' equity or security prices.
Why was the director changed?
The change is due to a reappointment by the parent company as part of internal organizational management.
What is the new director's role?
The new director, Hou Yu-Hsiang, is the Human Resources Director of Liyang Biotech, indicating the appointment of an experienced professional.